17.25 0.00 (0.00%)
After hours: 4:56PM EST
|Bid||17.02 x 800|
|Ask||21.00 x 800|
|Day's Range||17.20 - 18.07|
|52 Week Range||11.95 - 26.10|
|Beta (3Y Monthly)||-0.45|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2019 - Mar 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.38|
Does the December share price for AMAG Pharmaceuticals Inc (NASDAQ:AMAG) reflect it’s really worth? Today, I will calculate the stock’s intrinsic value by estimating the company’s future cash flows and Read More...
The ASH poster presentation focused on the durability of the improvements in several patient reported outcomes (PRO) measures in patients with iron deficiency anemia (IDA) following a single course of ferumoxytol (2 x 510 mg, 3-8 days apart) over a 6-month extension study period. In the initial phase 3 trial, patients treated with ferumoxytol showed improvement in quality of life compared to placebo as measured by fatigue-related symptoms.
WALTHAM, Mass., Nov. 29, 2018 -- As part of the company’s annual grant program to support research to reduce preterm birth and preeclampsia and associated complications, AMAG.
NEW YORK, Nov. 08, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
WALTHAM, Mass., Nov. 06, 2018 -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that company management will participate in the following investor conferences:.
AMAG reports wider than expected loss in the third quarter of 2018. The company completed the sale of Cord Blood Registry in August 2018.
The company's third-quarter financials did little to inspire confidence that its sales can withstand the launch of generic competition.
AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of 0.00% and 3.88%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Waltham, Massachusetts-based company said it had profit of 89 cents. Losses, adjusted for one-time gains and costs, were 77 cents per share. The results met Wall Street expectations. ...
Achieved strong third quarter financial performance and increased full year 2018 guidance Acquired AMAG-423 for severe preeclampsia, reaffirming the.
The Zacks Analyst Blog Highlights: Allergan, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and AMAG Pharmaceuticals
AMAG Pharmaceuticals (AMAG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WALTHAM, Mass., Oct. 25, 2018 -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its third quarter 2018 financial results will be released on Thursday, November.
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Investors need to pay close attention to AMAG Pharmaceuticals (AMAG) stock based on the movements in the options market lately.
In Q2 2018, partner Amag Pharmaceuticals (AMAG) reported revenues of $105.2 million for Makena, which is a year-over-year (or YoY) rise of 2.43%. According to Antares Pharma’s Q2 2018 conference call, this growth was driven mainly by the increased overall uptake of the product coupled with the launch of the Makena auto injector in the US market in March 2018. As per AMAG Pharmaceuticals’ estimates based on distributor dispensing data and physician market research data from its investor presentation, Makena accounted for a 51% share of the total market for preventing pre-term birth in at-risk women.
In H1 2018, Antares Pharma (ATRS) reported revenues of $26.86 million, which was a year-over-year (or YoY) rise of 6%. The revenue growth was mainly driven by a 27% YoY rise in product sales, which reached $22.04 million in H1 2018. Wall Street analysts expect Antares Pharma to report revenues of $59.56 million in fiscal 2018, which is a YoY rise of 9.25%.
AMAG Pharmaceuticals, Inc. (AMAG) and Endoceutics today announced an oral presentation regarding the effect of time since menopause, age, and previous hormone therapy on treatment efficacy of intravaginal 6.5 mg prasterone (INTRAROSA®) at the Annual Meeting of The North American Menopause Society (NAMS) in San Diego, California. David F. Archer, M.D., NCMP, will present the study results on Thursday, October 4th from 5:15 PM to 5:30 PM. Dr. Archer and colleagues analyzed combined data obtained from two prospective, randomized, double-blind, placebo-controlled clinical trials to evaluate the effect of daily intravaginal 6.5 mg INTRAROSA administered for 12 weeks to women who identified moderate to severe pain at sexual activity (dyspareunia) as their most bothersome symptom (MBS) of vulvar and vaginal atrophy, or VVA.
AMAG acquires global rights to develop/market DIF from Velo Bio to boost its maternal health portfolio. The candidate is under assessment for treating severe preeclampsia in pregnant women.